Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

NCT00064636 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non-Small Cell Lung Cancer
Other Solid Tumors

Interventions

DRUG: VELCADE TM (bortezomib) for Injection, or PS-341

Sponsor

Millennium Pharmaceuticals, Inc.